World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
126
Citations
93153
World Ranking
2873
National Ranking
1598

Overview

Andrew X. Zhu is affiliated with Harvard University in the United States and has made substantial contributions to the field of medicine, specializing primarily in oncology and hepatology. Their research focuses on liver-related cancers and diseases, encompassing hepatocellular carcinoma, cholangiocarcinoma, and broader hepatic oncology studies.

The scientist's work spans several key topics, including:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Liver Disease Diagnosis and Treatment

Andrew X. Zhu has contributed to numerous peer-reviewed publications, with frequent appearances in prominent journals such as the Journal of Clinical Oncology, Annals of Oncology, Journal of Hepatology, Clinical Cancer Research, and Liver Cancer. Their scholarly output reflects a strong presence in these high-impact venues.

Frequent collaborators in research include:

  • Richard S. Finn
  • Masatoshi Kudo
  • Peter R. Galle
  • Ann-Lii Cheng
  • Lipika Goyal

Selected recent papers exemplify the scope and focus of Andrew X. Zhu's work:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020), published in New England Journal of Medicine
  • Immunotherapies for hepatocellular carcinoma (2021), published in Nature Reviews Clinical Oncology
  • Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021), published in Journal of Hepatology
  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020), published in Journal of Clinical Oncology
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study (2020), published in The Lancet Oncology

The publication record and areas of study indicate a concentrated expertise in tumor biology, immunotherapy approaches for liver cancers, and clinical trial research design.

Andrew X. Zhu's main fields of study are medicine, with a significant subfield focus on oncology, hepatology, surgery, epidemiology, and cancer research. The interdisciplinary nature of their work is reflected in the integration of clinical oncology with molecular and diagnostic research.

Best Publications

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

    Jorge A. Marrero;Laura M. Kulik;Claude B. Sirlin;Andrew X. Zhu

  • AASLD guidelines for the treatment of hepatocellular carcinoma

    Julie K. Heimbach;Laura M. Kulik;Richard S. Finn;Claude B. Sirlin

  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

    Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda

  • EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

    Josep M. Llovet;Michel Ducreux;Riccardo Lencioni;Adrian M. Di Bisceglie

  • NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

    Al B Benson;Thomas A. Abrams;Edgar Ben-Josef;P. Mark Bloomston

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

    Josep M. Llovet;Adrian M. Di Bisceglie;Jordi Bruix;Barnett S. Kramer

  • Immunotherapies for hepatocellular carcinoma.

    Josep M Llovet;Josep M Llovet;Josep M Llovet;Florian Castet;Mathias Heikenwalder;Mala K Maini

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Differentiating the pathologies of cerebral malaria by postmortem parasite counts.

    Terrie E Taylor;Wenjiang J Fu;Wenjiang J Fu;Richard A Carr;Richard O Whitten

  • Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

    Cristina R. Ferrone;Giovanni Marchegiani;Theodore S. Hong;David P. Ryan

  • The role of signaling pathways in the development and treatment of hepatocellular carcinoma.

    S Whittaker;R Marais;A X Zhu

  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Teresa Macarulla;Milind M. Javle;Robin K. Kelley

  • Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

    Darrell R. Borger;Kenneth K. Tanabe;Kenneth C. Fan;Hector U. Lopez

  • Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

    Supriya K. Saha;Andrew X. Zhu;Charles S. Fuchs;Gabriel A. Brooks

  • Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment

    Mechteld C. De Jong;Hari Nathan;Georgios C. Sotiropoulos;Andreas Paul

Frequent Co-Authors

David P. Ryan
David P. Ryan Harvard University
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Cristina R. Ferrone
Cristina R. Ferrone Harvard University
Josep M. Llovet
Josep M. Llovet University of Barcelona
Dan G. Duda
Dan G. Duda Harvard University
Rakesh K. Jain
Rakesh K. Jain Harvard University
Dushyant V. Sahani
Dushyant V. Sahani University of Washington
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to a variety of online degree options beyond traditional MD programs. Many students choose healthcare administration as a flexible alternative. Accredited programs like the cahme master’s are highly regarded for those interested in leadership and management roles within healthcare.

For working nurses looking to advance, there are opportunities to earn a rn to bsn online with no clinicals degree. These online courses can be completed without in-person clinicals, making them more convenient for those balancing work or family responsibilities.

Advanced practice nurses can fast-track their education with the quickest dnp program options now available. These programs can often be finished in less time compared to traditional routes.

For those concerned about research requirements, there are now dnp programs without dissertation that streamline the process and focus on applied practice. Overall, the rise of online healthcare degrees opens new pathways and offers flexibility for a wide range of students.

Best Scientists Citing Andrew X. Zhu

Trending Scientists